Mohammed A Sharawey1, Eglal M Shawky1, Lamia H Ali2, Ahmed Ali Mohammed1, Hatem A Hassan1, Yasser M Fouad3. 1. Department of Internal Medicine, Faculty of Medicine, Minia University, El-Minia, Egypt. 2. Department of Clinical Pathology, Faculty of Medicine, Minia University, El-Minia, Egypt. 3. Department of Tropical Medicine, Faculty of Medicine, Minia University, El-Minia, Egypt. yasserfouad10@yahoo.com.
Abstract
BACKGROUND: Recent studies suggest that serum cystatin C (CysC) is a more sensitive marker of renal functions than serum creatinine (Cr). AIM: Evaluation of the clinical significance of cystatin C as a predictor of hepatorenal syndrome (HRS) in patients with liver cirrhosis, ascites, and normal serum Cr level. METHODS: Eighty patients with cirrhotic ascites were enrolled in this study (53 men and 27 women; age: 59.5 ± 7.5 years). All patients were subjected to full clinical assessment and laboratory investigations focussing on renal functions, glomerular filtration rate, and measurement of serum cystatin level. RESULTS: The Serum Cr and CysC levels were 1.04 ± 0.1 and 1.8 ± 0.8 mg/L, respectively. HRS developed in 18 patients during the follow-up period (6 months). Type 1 HRS was found in 5 patients and type 2 HRS was found in 13 patients with no significant difference between both types regarding baseline characteristics. Age (p < 0.001), albumin (p < 0.001), sodium (p < 0.005), cystatin C (p < 0.001), and e-GFRMDRD (estimated glomerular filtration rate-modification of the diet in renal disease) (p < 0.007) were significant dependent predictive factors for the development of HRS. The CysC level was the most independent predictive factor for HRS (OR, 2.1; 95% CI, 0.75-0.97; p < 0.002). Eighteen patients died during the follow-up period. Age (p < 0.001), INR (p < 0.001), e-GFRMDRD (p < 0.03), sodium (p < 0.01), MELD score (p < 0.05), albumin (p < 0.001), and CysC (p < 0.001) levels were significant dependent factors for predicting mortality. CysC (OR, 5.3; p < 0.006) level and INR (OR, 1.01; p < 0.006) were the most independent factors for predicting mortality. CONCLUSION: Serum CysC level may be considered a predictor of HRS and mortality in patients with liver cirrhosis and ascites.
BACKGROUND: Recent studies suggest that serum cystatin C (CysC) is a more sensitive marker of renal functions than serum creatinine (Cr). AIM: Evaluation of the clinical significance of cystatin C as a predictor of hepatorenal syndrome (HRS) in patients with liver cirrhosis, ascites, and normal serum Cr level. METHODS: Eighty patients with cirrhotic ascites were enrolled in this study (53 men and 27 women; age: 59.5 ± 7.5 years). All patients were subjected to full clinical assessment and laboratory investigations focussing on renal functions, glomerular filtration rate, and measurement of serum cystatin level. RESULTS: The Serum Cr and CysC levels were 1.04 ± 0.1 and 1.8 ± 0.8 mg/L, respectively. HRS developed in 18 patients during the follow-up period (6 months). Type 1 HRS was found in 5 patients and type 2 HRS was found in 13 patients with no significant difference between both types regarding baseline characteristics. Age (p < 0.001), albumin (p < 0.001), sodium (p < 0.005), cystatin C (p < 0.001), and e-GFRMDRD (estimated glomerular filtration rate-modification of the diet in renal disease) (p < 0.007) were significant dependent predictive factors for the development of HRS. The CysC level was the most independent predictive factor for HRS (OR, 2.1; 95% CI, 0.75-0.97; p < 0.002). Eighteen patients died during the follow-up period. Age (p < 0.001), INR (p < 0.001), e-GFRMDRD (p < 0.03), sodium (p < 0.01), MELD score (p < 0.05), albumin (p < 0.001), and CysC (p < 0.001) levels were significant dependent factors for predicting mortality. CysC (OR, 5.3; p < 0.006) level and INR (OR, 1.01; p < 0.006) were the most independent factors for predicting mortality. CONCLUSION: Serum CysC level may be considered a predictor of HRS and mortality in patients with liver cirrhosis and ascites.
Authors: J J Berenguer-Pina; J Noguera; F Cañizares; C Hernandez-Bernal; E Velasco-Conesa; C Lozano-Postigo; A Patiño; J Cabezuelo; F Acosta; P Martinez-Hernández; P Ramirez; P Parrilla Journal: Transplant Proc Date: 2002-02 Impact factor: 1.066
Authors: E Cholongitas; L Marelli; A Kerry; D W Goodier; D Nair; M Thomas; D Patch; A K Burroughs Journal: Am J Transplant Date: 2007-01-11 Impact factor: 8.086
Authors: E Randers; P Ivarsen; E J Erlandsen; E F Hansen; N K Aagaard; F Bendtsen; H Vilstrup Journal: Scand J Clin Lab Invest Date: 2002 Impact factor: 1.713
Authors: G Fernández-Esparrach; A Sánchez-Fueyo; P Ginès; J Uriz; L Quintó; P J Ventura; A Cárdenas; M Guevara; P Sort; W Jiménez; R Bataller; V Arroyo; J Rodés Journal: J Hepatol Date: 2001-01 Impact factor: 25.083
Authors: Brian Erly; William D Carey; Baljendra Kapoor; J Mark McKinney; Mathew Tam; Weiping Wang Journal: Semin Intervent Radiol Date: 2015-12 Impact factor: 1.513
Authors: Olga Baraldi; Chiara Valentini; Gabriele Donati; Giorgia Comai; Vania Cuna; Irene Capelli; Maria Laura Angelini; Maria Ilaria Moretti; Andrea Angeletti; Fabio Piscaglia; Gaetano La Manna Journal: World J Nephrol Date: 2015-11-06